Prostatic Neoplasms, Castration-Resistant - 21 Studies Found
| Not yet recruiting |
: Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA) : Prostatic Cancer, Castration-Resistant : 2016-08-08 : Drug: SXL01 |
| Recruiting |
: Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer : Prostate Cancer : 2015-04-15 :
|
| Recruiting |
: Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer : Metastatic Castration-Resistant Prostatic Cancer : 2014-09-30 :
|
| Terminated |
: F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer : Castration-resistant Prostate Cancer : 2013-08-01 : Device: F-Choline-PET |
| Completed |
: Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer :
: 2007-10-09 :
|
| Not yet recruiting |
: Combination Study of Guadecitabine and Pembrolizumab. :
: 2016-11-02 :
|
| Recruiting |
: Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases : Castration-Resistant Prostatic Cancer : 2015-03-20 : Drug: Radium-223 dichloride, (Xofigo, BAY88-8223) Dosage and treatment duration according to the decisio |
| RECRUITING |
: Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy : : 2024-11-21 : To evaluate the tolerability and safety of 225Ac-PSMA I&T in patients with metastatic prostate cancer |
| NOT_YET_RECRUITING |
: Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer : Prostatic Neoplasms, Castration-Resistant : 2024-11-21 : TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol |
| ACTIVE_NOT_RECRUITING |
: A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer : Prostatic Neoplasms, Castration-Resistant : 2024-11-21 : As provided in real-world setting |